Navigation Links
Sangamo BioSciences Reports Third Quarter 2009 Financial Results
Date:11/4/2009

----- ------ ------ ------ Loss from operations (4,804) (6,382) (16,987) (23,176) Interest and other income (loss), net (47) 42 793 1,448 Net loss $(4,851) $(6,340) $(16,194) $(21,728) ======= ======= ======== ======== Basic and diluted net loss per common share $(0.12) $(0.15) $(0.39) $(0.53) Shares used in computing basic and diluted net loss per common share 41,184 40,928 41,126 40,759 ====== ====== ====== ====== SELECTED BALANCE SHEET DATA September 30, 2009 December 31, 2008 ------------------ ----------------- Cash, cash equivalents, marketable securities and interest receivable $47,863 $65,025 Total assets 51,383 67,850 Total stockholders' equity 44,450 55,396

SOURCE Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
4. Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
5. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
6. Sangamo BioSciences Announces Presentation of Top-Line Statistically Significant Phase 2 Data in Diabetic Neuropathy at Society for Neuroscience Meeting
7. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
8. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
9. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
10. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Beckman Coulter to Host Annual Business Review 2Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 2Health News:Researchers identify barriers to HPV vaccination uptake in low-income populations 3Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 2Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 2Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 3Health News:Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009 4Health News:New National Study Spotlights Importance of Federal Medicare Funding to Propping-Up Seniors' Deteriorating State Medicaid Benefits and Services 2Health News:New National Study Spotlights Importance of Federal Medicare Funding to Propping-Up Seniors' Deteriorating State Medicaid Benefits and Services 3
Breaking Medicine Technology:Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Cancer survivors at greater risk of birth complications 3B special monitoring needed 50498 1Cancer survivors at greater risk of birth complications 3B special monitoring needed 50498 2Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 1Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 2Meltzer and Yancy to Lead American Heart Association in 2009 10 50496 3Calling All Runners 3A Join the Fight Against Cancer 50493 1Calling All Runners 3A Join the Fight Against Cancer 50493 2